Iran Press/Iran News: Ehsan Shamsi-Gooshki stated on Monday: "The most important step to start the clinical trial of the second Iranian vaccine has been done, and soon the Food and Drug Administration will issue a clinical trial permission."
He noted that after the issuance of the first clinical trial permission for the COVID vaccine belonging to Barakat Pharmaceutical Group and Shafa Darou companies, a phase one clinical trial permission was issued to test the vaccine produced by Razi Vaccine and Serum Research Institute.
He pointed out that a member of the Research Ethics Committee would be present during the clinical trial as a member of the Data Monitoring Committee and would oversee the proper conduct of the research process.
Shamsi highlighted that this vaccine is a recombinant protein whose technology differs from the previous permitted Iranian COVID vaccine (killed virus).
The clinical trial of the second Iranian COVID vaccine is performed by Razi Vaccine and Serum Research Institute in collaboration with Iran University of Medical Sciences, he added.
The first phase of clinical studies of human injection of the first COVID vaccine made by Iranian researchers called 'COVO-Iran Barakat' was performed on the volunteers on Tuesday (December 29) in the presence of the minister of health and medical education and the vice president for science and technology.
Several other research centers and institutes and knowledge-based companies are trying to make an Iranian COVID vaccine, which has achieved good results in this field.
In addition to live vectored and inactivated viruses, novel recombinant technologies are being used in the development of the COVID-19 vaccine. The advantage of recombinant vaccines is their greater response predictability and improved efficacy.
214
Read More:
Iran to begin 2nd phase of human trials of Iranian COVID vaccine
